The area under the cumulative incidence curve for CV-related mortality from baseline up to 48 months represents the restricted mean time lost (RMTL) due to CV mortality for the placebo group (shaded area, 342.3 days) (A) and for the bucindolol group (shaded area, 302.9 days) (B). The area under the cumulative incidence curve for non-CV-related mortality represents the RMTL due to non-CV mortality for the placebo group (shaded area, 52.0 days) (C) and for the bucindolol group (shaded area, 59.5 days) (D).

**Discussion**

The hazard itself is not easy to interpret heuristically. Without knowing the hazard function from the control group, an HR may not meaningfully summarize treatment effects for clinical decision-making. While the RMTL difference or ratio is model-free, a caveat is that the time window to define RMTL should be prespecified at the design stage based on clinical considerations. At the end of the study, one may select other times within the study duration for a sensitivity analysis.

In the presence of competing risks, quantifying treatment effects is more complex. If the treatment is effective in preventing CV deaths, one may observe an increasing risk of non-CV death at a later stage because death is unavoidable. Therefore, the comparison results should be presented simultaneously for all competing events and interpreted cautiously. The generalization of the proposal, including nonfatal competing events, is straightforward.

Lihui Zhao, PhD
Lu Tian, ScD
Brian Claggett, PhD
Marc Pfeffer, MD, PhD
Dae Hyun Kim, MD, ScD
Scott Solomon, MD
Lee-Jen Wei, PhD

**Author Affiliations:** Department of Preventive Medicine, Northwestern University, Chicago, Illinois (Zhao); Stanford Medical School, Stanford University, Stanford, California (Tian); Division of Cardiovascular, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (Claggett, Pfeffer, Solomon); Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (Kim); Department of Biostatistics, Harvard University, Boston, Massachusetts (Wei).

**Corresponding Author:** Lee-Jen Wei, PhD, Department of Biostatistics, Harvard University, 655 Huntington Ave, Boston, MA 02115 (wei@hsph.harvard.edu).

**Accepted for Publication:** January 18, 2018.

**Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Pfeffer reports receiving personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, DaCor, Gilead, GlaxoSmithKline, Janssen, Lilly USA, The Medicines Company, Merck, Novo Nordisk, Relypsa, Thrasos, Genzyme, and Teva and grants and personal fees from Novartis and Sanofi. He also holds a patent with Novartis for the use of inhibitors of renal artery stenosis in patients with myocardial infarction. Dr Kim reports receiving grant support from the National Institute on Aging and personal fees from Alosa Health. No other disclosures were reported.

**Published Online:** March 14, 2018. doi:10.1001/jamacardio.2018.0127

**Author Contributions:** Drs Wei, Claggett, and Tian had full access to the data from the β-Blocker Evaluation of Survival Trial and had full responsibility for the integrity of the data and the accuracy of data analysis. Drs Zhao and Tian equally contributed to this work and are co-first authors, and Drs Solomon and Wei have equally contributed to this work and are co-last authors.

**Concept and design:** Zhao, Tian, Solomon, Wei.

**Acquisition, analysis, or interpretation of data:** Zhao, Tian, Claggett, Pfeffer, Kim, Wei.

**Drafting of the manuscript:** Zhao, Tian, Claggett, Wei.

**Critical revision of the manuscript for important intellectual content:** All authors.

**Statistical analysis:** Zhao, Tian.

**Funding/Sponsorship:** This work was partially supported by grants and contracts from the National Institutes of Health.

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Contributions:** We thank Michael Pencina, PhD, Duke Clinical Research Institute, and 3 reviewers for their constructive suggestions and comments on the article. They were not compensated for their contributions.


**CORRECTION**

**Omission in Correspondence Address:** In the Original Investigation titled “Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction,”1 published online February 14, 2018, there was an omission in the correspondence address. The address should have been listed as follows: “Ali Ahmed, MD, MPH, Center for Health and Aging, Veterans Affairs Medical Center, 1120 Irving St NW, Ste 1290, Washington, DC 20422 (ali.ahmed@va.gov).” This article was corrected online.